<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935764</url>
  </required_header>
  <id_info>
    <org_study_id>FDZL-FCI</org_study_id>
    <nct_id>NCT02935764</nct_id>
  </id_info>
  <brief_title>FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients</brief_title>
  <official_title>Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Regimen (FOLFIRI) Versus Irinotecan Monodrug as Second-line Treatment in Metastatic Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <brief_summary>
    <textblock>
      This study is designed to compare the efficacy and safety of FOLFIRI regimen with irinotecan
      monodrug in the treatment of advanced colorectal cancer patients in the second-line setting.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life questionnaire</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-fluorouracil,folinate combined with irinotecan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IRINOTECAN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180 mg/m2 iv gtt, d1</description>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_label>IRINOTECAN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>5-FU 400mg/m2 iv, 2400mg/m2 civ 46h</description>
    <arm_group_label>FOLFIRI</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>400mg/m2 iv gtt,d1</description>
    <arm_group_label>FOLFIRI</arm_group_label>
    <other_name>LV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18-70 years with histologically or cytologically confirmed advanced colorectal
             adenocarcinoma

          -  Eastern Cooperative Oncology Group performance status of 0 to 2

          -  life expectancy of â‰¥ 3 months

          -  patients who had failed first-line treatment with either XELOX (capecitabine combined
             with oxaliplatin) or FOLFOX (5-fluorouracil/leucovorin with oxaliplatin)

          -  at least one measurable disease lesion according to the Response Evaluation Criteria
             in Solid Tumors (RECIST 1.1) criteria

          -  have adequate bone marrow, hepatic, and renal function

        Exclusion Criteria:

          -  patients with previous chronic inflammatory bowel disease, chronic diarrhea or
             recurrent bowel obstruction

          -  patients with symptomatic brain metastases

          -  active clinical severe infection

          -  previously received irinotecan

          -  dihydropyrimidine dehydrogenase (DPD) enzyme adequate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Weijian Guo</investigator_full_name>
    <investigator_title>Vice Director of Department of Medical Oncology, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

